Amarin (AMRN) Vascepa RXs Outpace Industry as of 06/07 - Cantor Fitzgerald

June 14, 2019 9:00 AM EDT Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login